Evidence map›Paper›PMID 32153793›Full record

Trial reportOpen heart2020

Clinical and echocardiographic characteristics of individuals aged 75/76 years old with screening-detected elevated NT-proBNP levels.

Faris Al-Khalili, Katrin Kemp-Gudmundsdottir, Emma Svennberg, Tove Fredriksson, Viveka Frykman, Leif Friberg, Mårten Rosenqvist, Johan Engdahl

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Open heart, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. NT-proBNP in the very old population: reference values and heart failure specificity from the AugUR-study.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Article
  2. Article
  3. The role of NT-proBNP in screening for atrial fibrillation in hypertensive disease.International journal of cardiology. Heart & vasculature · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Faris Al-KhaliliDepartment of Clinical Sciences, Karolinska Institutet, Danderyd University Hospital, Stockholm, Sweden.ORCID 0000-0002-8849-7052
Katrin Kemp-GudmundsdottirDepartment of Clinical Sciences, Karolinska Institutet, Danderyd University Hospital, Stockholm, Sweden.
Emma SvennbergDepartment of Clinical Sciences, Karolinska Institutet, Danderyd University Hospital, Stockholm, Sweden.
Tove FredrikssonDepartment of Clinical Sciences, Karolinska Institutet, Danderyd University Hospital, Stockholm, Sweden.
Viveka FrykmanDepartment of Clinical Sciences, Karolinska Institutet, Danderyd University Hospital, Stockholm, Sweden.
Leif FribergDepartment of Clinical Sciences, Karolinska Institutet, Danderyd University Hospital, Stockholm, Sweden.
Mårten RosenqvistDepartment of Clinical Sciences, Karolinska Institutet, Danderyd University Hospital, Stockholm, Sweden.
Johan EngdahlDepartment of Clinical Sciences, Karolinska Institutet, Danderyd University Hospital, Stockholm, Sweden.
Karolinska Institutet · SESophiahemmet Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: High plasma levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) indicate increased probability of congestive heart failure (CHF) and atrial fibrillation (AF) and are associated with poor prognosis. Objective: We aimed to describe the clinical and echocardiographic characteristics of a population of individuals aged 75/76 years old with NT-proBNP ≥900 ng/L without previously known CHF or AF. Methods: All individuals aged 75/76 years in the Stockholm region were randomised to a screening study for AF. Half of them were invited to screening. Of those invited, 49.5% agreed to participate. Individuals with NT-proBNP ≥900 ng/L without known CHF were invited for further clinical evaluation. Results: Among 6315 participants without AF who had NT-proBNP sampled, 102 without previously known CHF had ≥900 ng/L. Of these, 93 completed further clinical investigations. In the population that was clinically investigated, 53% were female, and the median NT-proBNP was 1200 ng/L. New AF was found in 28 (30%). The NT-proBNP value in this group was not significantly different from those where AF was not detected (median 1285 vs 1178 ng/L). Patients with newly detected AF had larger left atrial volume and higher pulmonary artery pressure than those without AF. Preserved left ventricular ejection fraction (≥50%) was found in 86% of the participants, mid-range ejection fraction (40%-49%) in 3.2% and reduced ejection fraction (<40%) in 10.8%. Thirteen patients (14%) had other serious cardiac disorders that required medical attention. Conclusion: Elderly individuals with NT-proBNP levels ≥900 ng/L constitute a population at high cardiovascular risk even in the absence of diagnosed CHF or AF, and therefore merit further investigation.

Indexed as

Echocardiography, DopplerAgedAge FactorsAsymptomatic DiseasesAtrial FibrillationBiomarkersElectrocardiographyFemaleHeart RateHumansMaleMass ScreeningNatriuretic Peptide, BrainPeptide FragmentsPredictive Value of TestsRisk FactorsBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)atrial fibrillationechocardiographyheart failure

Identifiers

PMID32153793
PMCPMC7046938
OpenAlexW3008244998

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.